Patents by Inventor Mohsen Badiee

Mohsen Badiee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Visual cycle modulators
    Patent number: 12144788
    Abstract: A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: November 19, 2024
    Assignees: CASE WESTERN RESERVE UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
    Inventors: Krzysztof Palczewski, Philip Kiser, Jianye Zhang, Mohsen Badiee, Gregory Tochtrop
  • VISUAL CYCLE MODULATORS
    Publication number: 20220175700
    Abstract: A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).
    Type: Application
    Filed: February 22, 2022
    Publication date: June 9, 2022
    Inventors: Krzysztof Palczewski, Philip Kiser, Jianye Zhang, Mohsen Badiee, Gregory Tochtrop
  • Visual cycle modulators
    Patent number: 11253489
    Abstract: A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 22, 2022
    Assignees: CASE WESTERN RESERVE UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
    Inventors: Krzysztof Palczewski, Philip Kiser, Jianye Zhang, Mohsen Badiee, Gregory Tochtrop
  • METHODS AND USES OF ENZYMATIC LABELING OF ADP-RIBOSE CONTAINING MOLECULES
    Publication number: 20210156847
    Abstract: Described is ELTA (Enzymatic Labeling of Terminal ADP-ribose) to label free, protein-conjugated, or nucleic acid-conjugated ADP-ribose monomer and polymers at their 2?-OH termini. When coupled with different chemical analogs, ELTA can be used for various applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.
    Type: Application
    Filed: April 2, 2019
    Publication date: May 27, 2021
    Inventors: Anthony K.L. Leung, Yoshinari Ando, Robert L McPherson, Mohsen Badiee, Elad Elkayam